The ongoing Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, declared in May 2026 and now the country's deadliest with over 5,500 confirmed cases and roughly 2,600 deaths across six provinces as of late August, dominates trader focus. Rapid community transmission, conflict-driven mobility, and the absence of approved vaccines or treatments for this strain have fueled exponential growth, outpacing contact tracing and response efforts despite WHO's public health emergency designation. Imported cases reached Uganda (contained with no sustained local spread) and France, while neighboring nations face elevated risk from porous borders and displacement. Ongoing surveillance expansions, potential vaccine pilots, and any new cross-border detections will shape resolution probabilities through year-end.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedWhich countries will have an Ebola case in 2026?
Which countries will have an Ebola case in 2026?
$34,880 Vol.
Dec 30, 2026
South Sudan
62%
Rwanda
28%
Burundi
30%
United States
24%
Canada
21%
Kenya
43%
India
14%
Republic of the Congo
27%
Nigeria
16%
Ethiopia
49%
Somalia
34%
China
13%
$34,880 Vol.
South Sudan
$2,171 Vol.
62%
Rwanda
$2,128 Vol.
28%
Burundi
$200 Vol.
30%
United States
$10,215 Vol.
24%
Canada
$1,360 Vol.
21%
Kenya
$235 Vol.
43%
India
$732 Vol.
14%
Republic of the Congo
$12,170 Vol.
27%
Nigeria
$25 Vol.
16%
Ethiopia
$107 Vol.
49%
Somalia
$71 Vol.
34%
China
$3,512 Vol.
13%
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.The ongoing Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, declared in May 2026 and now the country's deadliest with over 5,500 confirmed cases and roughly 2,600 deaths across six provinces as of late August, dominates trader focus. Rapid community transmission, conflict-driven mobility, and the absence of approved vaccines or treatments for this strain have fueled exponential growth, outpacing contact tracing and response efforts despite WHO's public health emergency designation. Imported cases reached Uganda (contained with no sustained local spread) and France, while neighboring nations face elevated risk from porous borders and displacement. Ongoing surveillance expansions, potential vaccine pilots, and any new cross-border detections will shape resolution probabilities through year-end.
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Market Opened: May 22, 2026, 12:35 PM ET
Volume
$34,880End Date
Dec 31, 2026Market Opened
May 22, 2026, 12:35 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.The ongoing Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, declared in May 2026 and now the country's deadliest with over 5,500 confirmed cases and roughly 2,600 deaths across six provinces as of late August, dominates trader focus. Rapid community transmission, conflict-driven mobility, and the absence of approved vaccines or treatments for this strain have fueled exponential growth, outpacing contact tracing and response efforts despite WHO's public health emergency designation. Imported cases reached Uganda (contained with no sustained local spread) and France, while neighboring nations face elevated risk from porous borders and displacement. Ongoing surveillance expansions, potential vaccine pilots, and any new cross-border detections will shape resolution probabilities through year-end.
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Volume
$34,880End Date
Dec 31, 2026Market Opened
May 22, 2026, 12:35 PM ETResolver
0x65070BE91...The ongoing Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, declared in May 2026 and now the country's deadliest with over 5,500 confirmed cases and roughly 2,600 deaths across six provinces as of late August, dominates trader focus. Rapid community transmission, conflict-driven mobility, and the absence of approved vaccines or treatments for this strain have fueled exponential growth, outpacing contact tracing and response efforts despite WHO's public health emergency designation. Imported cases reached Uganda (contained with no sustained local spread) and France, while neighboring nations face elevated risk from porous borders and displacement. Ongoing surveillance expansions, potential vaccine pilots, and any new cross-border detections will shape resolution probabilities through year-end.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions